Jazz and AbCellera Enter into a Multi-Program Collaboration to Develop Next-Generation T-Cell Engaging Bispecific Antibodies, Valued at up to $4 Billion
Deal Structure and Financial Terms
Jazz Pharmaceuticals (JAZZ) and AbCellera Biologics (ABCL) announced a collaboration agreement on June 17, 2026, to co-develop next-generation T-cell engaging (TCE) bispecific antibodies. AbCellera will receive an upfront payment of $56 million for the initial two programs and an additional $28 million upon initiation of the third program within 12 months. Each program includes option fees, development, regulatory, and commercial milestone payments, totaling up to $792 million, with royalties on net sales ranging from the mid-single to low double-digit percentage. With a total of five programs, the deal represents a significant platform agreement valued at approximately $4 billion.
Roles and Technology Synergies
AbCellera will leverage its AI-driven, single-cell screening, microfluidics, and high-throughput sequencing integrated antibody discovery engine to identify candidates, conduct IND-enabling studies, and manufacture clinical supply. Jazz will have the option to exclusively develop and commercialize each program globally. AbCellera CEO Carl Hansen stated that TCEs induce highly targeted immune activation, while Jazz Oncology CSO Josh Allen emphasized its alignment with their rare disease strategy.
Therapeutic Strategy: Expanding into Solid Tumors
Existing TCE therapies, such as Amgen's Blincyto (blinatumomab) and Tarlatamab, have primarily been approved and marketed for hematologic malignancies. This collaboration explicitly targets gastrointestinal (GI) cancers and other solid tumors, representing a strategic shift to expand the therapeutic application of TCEs beyond hematologic malignancies. Key challenges in developing TCEs for solid tumors include managing immune evasion within the tumor microenvironment (TME) and cytokine release syndrome (CRS). AbCellera's bispecific design is expected to address these challenges.
Competitive Landscape and Market Outlook
The global TCE market is projected to grow from approximately $10.6 billion in 2026 to $49.7 billion in 2035, with a compound annual growth rate of 18.7%. In the solid tumor TCE space, Janux Therapeutics (JANX) entered into an $850 million TRACTr (masked TCE) partnership with BMS, but experienced a setback with the discontinuation of the JANX008 Phase 1 trial. Vir Biotechnology's (VIR) VIR-5500 has demonstrated potential in a Phase 1 trial for prostate cancer, with 7 out of 12 patients showing PSA50 reduction. Jazz-AbCellera's entry adds a differentiated focus on GI cancers to this competitive landscape.
Context within Jazz's Oncology Portfolio
Jazz is transitioning from a traditional sleep and epilepsy drug company to an oncology-focused organization. This includes Phase 3 data for Ziihera (zanidatamab) in first-line HER2+ gastroesophageal adenocarcinoma (GEA), expanded approval for Zepzelca (lurbinectedin) in first-line extensive-stage small cell lung cancer (ES-SCLC), and the development of dordaviprone, acquired through the Chimerix acquisition, for H3 K27M-mutant diffuse midline glioma. This collaboration with AbCellera aims to significantly expand its early-stage (preclinical discovery) pipeline and secure long-term growth drivers.
With the global TCE market projected to grow from $10.6 billion in 2026 to $49.7 billion in 2035, Jazz is proactively entering the GI cancer and solid tumor space, addressing a significant unmet need beyond hematologic malignancies, and establishing a next-generation oncology growth pillar alongside zanidatamab and lurbinectedin. AbCellera secures $56 million in upfront payments and up to $792 million in program milestones, generating early-stage revenue and reaffirming its platform value through its largest external partnership since the Eli Lilly COVID-19 antibody collaboration. The discontinuation of Janux's JANX008 Phase 1 trial highlights the technical challenges of developing TCEs for solid tumors, where AbCellera's bispecific antibody design capabilities may serve as a key differentiator. However, as the collaboration is currently in the preclinical discovery phase, IND submission is expected to take at least 2-3 years, and investors should monitor the decision on exercising options for each program and the release of initial preclinical data.
Source: BioPharma Dive (rss)